# Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure

Study · id `cardio:ct-nct02501811` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02501811](<https://clinicaltrials.gov/study/NCT02501811>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02501811

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 125 participants.

## Technical summary

Registry record NCT02501811. Randomized; quadruple masking; primary purpose treatment. Start 2015-10 (registry gives no type); primary completion 2020-06-25 (actual). Results posted on 2021-04-26.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 125 participants (enrolled count; ClinicalTrials.gov record NCT02501811, source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)
- Start date: 2015-10 (registry gives no type) (ClinicalTrials.gov record NCT02501811, source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)
- Primary completion: 2020-06-25 (actual) (ClinicalTrials.gov record NCT02501811, source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)
- Completion: 2020-07-22 (actual) (ClinicalTrials.gov record NCT02501811, source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)
- Results first posted: 2021-04-26 (ClinicalTrials.gov record NCT02501811, source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT02501811, source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02501811-2021-04-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
- Acronym: CONCERT-HF
- Condition: Ischemic Cardiomyopathy
- Intervention (Biological): Mesenchymal Stem Cells (MSC)
- Intervention (Biological): c-kit+ cells
- Intervention (Biological): Placebo (Plasmalyte A)
- Lead sponsor: The University of Texas Health Science Center, Houston
- Lead sponsor class: OTHER
- Collaborator: National Heart, Lung, and Blood Institute (NHLBI)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: The University of Texas Health Science Center, Houston (`cardio:org-the-university-of-texas-health-science-center-houston`)
- Registry lists this organization as a collaborator: National Heart, Lung, and Blood Institute (`cardio:nhlbi`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Changes in Circulating Biomarkers in Patients With Ischemic Heart Failure After Treatment With Autologous Mesenchymal Stromal Cells and c-Kit-Positive Cardiac Cells, Alone or in Combination: Results From the Cardiovascular Cell Therapy Research Network CONCERT-HF Clinical Trial (`cardio:pubmed-42003602`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: fbe68d86c91da07f1c6df11f63a278fd7f962ae101220be572992cac36309189
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
